Here are 1-3 brief analogies for ChronoScale (CHRN):

• Like a Medtronic for robotic exoskeletons, designing advanced wearable suits to aid medical rehabilitation.
• Think of it as the Caterpillar of wearable industrial 'power suits,' creating exoskeletons to help workers perform strenuous tasks.

Major Customers of Ekso Bionics Holdings, Inc. (CHRN)

Based on the provided company description, Ekso Bionics Holdings, Inc. (CHRN) primarily sells and rents its products to other companies and institutions, rather than directly to individuals. The description does not list specific customer company names.

The major categories of customers served by Ekso Bionics are:

• Medical Facilities and Rehabilitation Centers: These institutions purchase or rent EksoHealth segment products, such as the EksoNR wearable bionic suit, for use by physical therapists and physicians in treating patients with conditions like acquired brain injury, stroke, and spinal cord injury.
• Industrial and Commercial Enterprises: Companies in various industries acquire EksoWorks segment exoskeleton devices to assist their able-bodied employees with difficult, repetitive work tasks, aiming to improve efficiency and reduce physical strain.

Cenly Chen, Chief Executive Officer

Cenly Chen was appointed Chief Executive Officer and a member of the board of ChronoScale. She brings over 20 years of experience in enterprise infrastructure and high-performance computing platforms. Prior to joining ChronoScale, she served as Chief Growth Officer, Senior Vice President, and Managing Director at Super Micro Computer, Inc. (NASDAQ:SMCI), where she led global growth initiatives across AI and enterprise infrastructure markets. During her tenure at Supermicro, she played a key role in transforming the company into a leading AI infrastructure provider, expanding its revenue to over $40 billion and its workforce to more than 7,000 employees. Her experience also includes roles at Ericsson, AT&T, and Global Crossing.

Jerome Wong, Chief Financial Officer

Jerome Wong serves as the Chief Financial Officer of ChronoScale Holdings Corporation. He brings over 20 years of experience in finance, accounting, and strategy, primarily focusing on high-technology and life sciences companies in the public sector. Mr. Wong initially joined Ekso Bionics (now ChronoScale) as Corporate Controller in May 2017 before being promoted to CFO in 2022. His prior experience includes serving as a corporate controller or assistant corporate controller at public companies such as ABM Industries, Inc. (July 2006-September 2008), XOMA Corporation (July 2009-October 2014), and Pattern Energy Group Inc. (October 2014-December 2015). Earlier in his career, he worked as an Audit Manager at Deloitte & Touche, LLP.

Lawrence Lam, Chief Product Officer

Lawrence Lam is the Chief Product Officer at ChronoScale. He has over 20 years of experience in building and scaling global cloud and AI platforms. He has contributed to over $20 billion in AI infrastructure deployments worldwide, significantly aiding the success of Supermicro AI solutions focused on full-stack AI accelerators, low-latency storage, and advanced AI networking technologies. At ChronoScale, he is responsible for the global product vision, accelerating go-to-market strategies, and defining platform strategies for compute-as-a-service and next-generation AI services.

Raj Jegannathan, Chief Technology Officer

Raj Jegannathan is the Chief Technology Officer of ChronoScale. He joined the company after more than thirteen years at Tesla, where he most recently served as Vice President and reported directly to Elon Musk. At Tesla, he was responsible for a broad portfolio that included AI infrastructure, large-scale GPU clusters, storage systems, global information security, and enterprise technology platforms. His role at ChronoScale includes leading platforms, engineering, infrastructure, enterprise AI, data, IT, and information security.

Clear Emerging Threats for Ekso Bionics Holdings, Inc. (CHRN):

• Disruptive breakthroughs in non-mechanical medical therapies: Significant advancements in regenerative medicine, targeted neuro-stimulation, or advanced brain-computer interfaces that could offer superior or more direct recovery mechanisms for neurological conditions such as acquired brain injury, stroke, and spinal cord injury. These emerging therapies could potentially reduce or eliminate the need for extensive physical rehabilitation utilizing external robotic exoskeletons.
• Accelerated adoption of advanced industrial robotics and automation: The continued rapid development and deployment of autonomous robots and collaborative robots (cobots) capable of performing difficult, repetitive industrial tasks could increasingly replace human labor in manufacturing and logistics. This trend could diminish the market demand for human-worn assistive devices like the EksoWorks exoskeletons, which are designed to augment able-bodied users performing such tasks.

The addressable markets for Ekso Bionics Holdings, Inc.'s main products and services, which include medical and industrial exoskeletons, are substantial and growing globally.

Medical/Rehabilitation Exoskeletons (EksoHealth, EksoNR, EksoUE)

The global medical exoskeleton market was valued at approximately USD 595.40 million in 2021 and is projected to reach USD 3.81 billion by 2027, demonstrating a compound annual growth rate (CAGR) of 36.29% from 2022 to 2027. Another estimate placed the global medical exoskeleton market at USD 1.09 billion in 2024, with a projection to grow to USD 7.15 billion by 2034 at a CAGR of roughly 20.7%. The market for robotic rehabilitation and exoskeleton devices, which includes products like EksoNR and EksoUE, was valued at USD 2.18 billion in 2025 and is expected to reach USD 6.81 billion by 2033, growing at a CAGR of 15.30% from 2026 to 2033. The global rehabilitation exoskeleton market specifically was valued at USD 2.8 billion in 2025 and is projected to reach USD 8.9 billion by 2034, with a CAGR of 13.8% from 2026 to 2034.

North America consistently holds the largest share in the medical exoskeleton market, accounting for approximately 40.00% of the revenue in 2021 and 46.16% in 2025. This region is also expected to witness significant incremental growth.

Industrial Exoskeletons (EksoWorks)

The global industrial exoskeleton market was valued at USD 330 million in 2024 and is projected to reach approximately USD 1.62 billion by 2030, exhibiting a CAGR of 30.2%. Another report estimated the industrial exoskeleton market size at USD 0.97 billion in 2025, growing to USD 1.65 billion by 2030 with a CAGR of 11.4%.

North America was the largest region in the industrial exoskeleton market in 2025, while Asia-Pacific is identified as the fastest-growing region.

Expected Drivers of Future Revenue Growth for Ekso Bionics Holdings, Inc. (formerly identified as ChronoScale (CHRN))

Over the next 2-3 years, Ekso Bionics Holdings, Inc., which the user identified with the symbol CHRN, is expected to drive future revenue growth through several key initiatives in its medical and industrial exoskeleton segments:

1. Expanded Adoption and Reimbursement for Personal Medical Exoskeletons: A significant driver of revenue growth is the expanding market for personal medical exoskeletons, particularly with the availability of Medicare reimbursement for the Ekso Indego Personal device since April 2024. This enables a broader patient population with spinal cord injuries to utilize the device for at-home and community use. The company has already identified over 50 qualified Medicare candidates and established partner agreements to support this initiative, which is expected to translate into increased sales.
2. Introduction and Commercialization of New Products and Software: Ekso Bionics is enhancing its product portfolio through new launches and expanded distribution. The company initiated the distribution of BalanceTutor, with sales anticipated to commence in the second quarter of 2026. Furthermore, a limited clinical study for the Nomad exoskeleton is underway, targeting general commercialization by late 2026. Additionally, the January 2024 introduction of GaitCoach software, which complements the EksoNR exoskeleton by providing real-time feedback for rehabilitation, is expected to enhance rehabilitation processes and patient outcomes, thereby increasing the value and adoption of their EksoNR devices.
3. Increased Penetration in Medical Rehabilitation Markets with Expanded Indications: The company has broadened its addressable patient population for medical exoskeletons. EksoNR, its wearable bionic suit, received FDA clearance for use with acquired brain injury in 2020 and multiple sclerosis in 2021, making it the first and only exoskeleton cleared for these indications in the market. Continued expansion into leading rehabilitation hospitals globally for products like EksoNR and EksoGT is expected to contribute to revenue growth.
4. Potential Rebound and Growth in the EksoWorks (Industrial) Segment: While the enterprise health segment has experienced some softness due to macroeconomic uncertainties, the overall market for industrial exoskeletons remains robust, driven by the need to reduce work-related injuries and enhance worker productivity. A recovery in enterprise sales and the resolution of previous order delays could lead to renewed growth within the EksoWorks segment, which designs and markets devices for able-bodied users performing demanding repetitive tasks [cite: 3, BACKGROUND].

Share Issuance

• In February 2026, Ekso Bionics Holdings, Inc. (which later became ChronoScale) issued 138,216,820 new common shares to acquire 100% of Applied Digital Cloud Corporation, with the contributor expected to own about 97% of the combined company.
• In January 2026, Ekso Bionics completed a private placement of Series B Convertible Preferred Stock, convertible into an aggregate of 711,922 shares of common stock, generating approximately $5.3 million in net proceeds.
• In May 2026, in connection with the business combination, the company agreed to sell and issue 1,311,407 shares of Common Stock in a PIPE investment for gross proceeds of approximately $15.75 million.

Inbound Investments

• Ekso Bionics Holdings, Inc. received approximately $5.3 million in net proceeds from a private placement of Series B Convertible Preferred Stock in January 2026.
• In May 2026, a PIPE investment generated approximately $15.75 million from the sale of 1,311,407 shares of Common Stock in connection with the business combination.

Outbound Investments

• Ekso Bionics Holdings's most recent acquisition was a merger with Indego on December 5, 2022.

Capital Expenditures

• Ekso Bionics Holdings, Inc. reported no capital expenditure in Q1 2026.
• For fiscal year 2025, nearly all cash pressure came from operations rather than heavy capital spending, with operating cash flow at -$11.8M and free cash flow at -$12.0M.